Douglas Russo
Research Subjects
Douglas Russo has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Rinath Jeselsohn
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
84 shared publications - Agostina Nardone
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
77 shared publications - Nabihah Tayob
Department of Data Science, Dana-Farber Cancer Institute, Boston, USA
64 shared publications - Sara M. Tolaney
Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
64 shared publications - Cristina Guarducci
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
51 shared publications - Avery Feit
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
50 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
Purpose:Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC).Patients and Methods:We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability.Results:A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%).Conclusions:Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
Purpose:Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC).Patients and Methods:We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability.Results:A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%).Conclusions:Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplementary tables 1-4 and supplementary figure legend
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplementary tables 1-4 and supplementary figure legend
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 6: Evolutionary analysis of longitudinal plasma ctDNA samples
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 6: Evolutionary analysis of longitudinal plasma ctDNA samples
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 1: Consort diagram
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 1: Consort diagram
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 5: SSNVs detected in the cancer-related genes across 68 ctDNA WES samples
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 5: SSNVs detected in the cancer-related genes across 68 ctDNA WES samples
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 2: Plasma circulating tumor DNA (ctDNA) collection and analysis
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 2: Plasma circulating tumor DNA (ctDNA) collection and analysis
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 3: Plasma circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics determined with ULP-WGS
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 3: Plasma circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics determined with ULP-WGS